Rapid induction of antigen-specific CD4
2019-nCoV Vaccine mRNA-1273
Adult
Antibodies, Neutralizing
/ blood
Antibodies, Viral
/ blood
Antigens, CD
/ metabolism
Antigens, Differentiation, T-Lymphocyte
/ metabolism
BNT162 Vaccine
CD8-Positive T-Lymphocytes
/ immunology
COVID-19
/ immunology
COVID-19 Vaccines
/ immunology
Female
Humans
Immunity, Cellular
Immunity, Humoral
Immunization, Secondary
Immunologic Memory
Lectins, C-Type
/ metabolism
Lymphocyte Activation
Male
Middle Aged
Peptides
/ immunology
SARS-CoV-2
/ physiology
Spike Glycoprotein, Coronavirus
/ immunology
Th1 Cells
/ immunology
Vaccination
Young Adult
AIM
SARS-CoV-2
T cells
T follicular helper
Tfh
Th1
activation induced markers
immunological memory
mRNA vaccine
Journal
Immunity
ISSN: 1097-4180
Titre abrégé: Immunity
Pays: United States
ID NLM: 9432918
Informations de publication
Date de publication:
14 09 2021
14 09 2021
Historique:
received:
22
04
2021
revised:
23
06
2021
accepted:
02
08
2021
pubmed:
29
8
2021
medline:
24
9
2021
entrez:
28
8
2021
Statut:
ppublish
Résumé
SARS-CoV-2 mRNA vaccines have shown remarkable clinical efficacy, but questions remain about the nature and kinetics of T cell priming. We performed longitudinal antigen-specific T cell analyses on healthy SARS-CoV-2-naive and recovered individuals prior to and following mRNA prime and boost vaccination. Vaccination induced rapid antigen-specific CD4
Identifiants
pubmed: 34453880
pii: S1074-7613(21)00308-3
doi: 10.1016/j.immuni.2021.08.001
pmc: PMC8361141
pii:
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Antigens, CD
0
Antigens, Differentiation, T-Lymphocyte
0
CD69 antigen
0
COVID-19 Vaccines
0
Lectins, C-Type
0
Peptides
0
Spike Glycoprotein, Coronavirus
0
2019-nCoV Vaccine mRNA-1273
EPK39PL4R4
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
2133-2142.e3Subventions
Organisme : NIAID NIH HHS
ID : T32 AI070077
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009140
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI082630
Pays : United States
Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests S.E.H. has received consultancy fees from Sanofi Pasteur, Lumen, Novavax, and Merk for work unrelated to this study. E.J.W. is a consultant or an adviser for Merck, Elstar, Janssen, Related Sciences, Synthekine, and Surface Oncology. E.J.W. is a founder of Surface Oncology and Arsenal Biosciences. E.J.W. is an inventor on a patent (U.S. Patent No. 10,370,446) submitted by Emory University that covers the use of PD-1 blockade to treat infections and cancer. A.S. is a consultant for Gritstone, Flow Pharma, CellCarta, Arcturus, Oxfordimmunotech, and Avalia. La Jolla Institute for Immunology has filed for patent protection for various aspects of T cell epitope and vaccine design work.
Références
Infect Immun. 2007 Jul;75(7):3556-60
pubmed: 17438031
Nat Med. 2021 Jul;27(7):1280-1289
pubmed: 34017137
Euro Surveill. 2021 Feb;26(6):
pubmed: 33573712
Annu Rev Immunol. 2011;29:621-63
pubmed: 21314428
Immunity. 2016 Jun 21;44(6):1379-91
pubmed: 27287409
Immunity. 2020 Dec 15;53(6):1281-1295.e5
pubmed: 33296685
Lancet Microbe. 2022 Jan;3(1):e21-e31
pubmed: 34778853
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Nature. 2017 Dec 21;552(7685):362-367
pubmed: 29236685
bioRxiv. 2021 Mar 01;:
pubmed: 33688655
Mult Scler. 2020 Sep;26(10):1261-1264
pubmed: 32762494
JAMA. 2020 Oct 20;324(15):1495-1496
pubmed: 33044484
Sci Immunol. 2021 Apr 15;6(58):
pubmed: 33858945
Trends Immunol. 2014 Sep;35(9):436-42
pubmed: 24998903
medRxiv. 2021 Feb 05;:
pubmed: 33564797
Nat Med. 2003 Sep;9(9):1131-7
pubmed: 12925846
JAMA. 2021 Apr 13;325(14):1467-1469
pubmed: 33646292
Nature. 2020 Oct;586(7830):594-599
pubmed: 32998157
Sci Immunol. 2017 Feb;2(8):
pubmed: 28620653
N Engl J Med. 2020 Nov 12;383(20):1920-1931
pubmed: 32663912
Pediatr Allergy Immunol. 2020 Jul;31(5):565-569
pubmed: 32319118
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
Nature. 1999 Oct 14;401(6754):708-12
pubmed: 10537110
Med (N Y). 2021 Jun 11;2(6):682-688.e4
pubmed: 33851143
J Clin Invest. 2021 Jun 15;131(12):
pubmed: 33939647
Nature. 2006 Jun 15;441(7095):890-3
pubmed: 16778891
Clin Dev Immunol. 2012;2012:925135
pubmed: 22474485
J Immunol Methods. 2003 Oct 1;281(1-2):65-78
pubmed: 14580882
PLoS One. 2017 Oct 24;12(10):e0186998
pubmed: 29065175
Front Immunol. 2018 Nov 20;9:2692
pubmed: 30515169
Nat Immunol. 2009 Aug;10(8):864-71
pubmed: 19578368
Science. 2020 Sep 4;369(6508):
pubmed: 32669297
N Engl J Med. 2020 Dec 17;383(25):2427-2438
pubmed: 32991794
Immunity. 2015 Sep 15;43(3):591-604
pubmed: 26362266
N Engl J Med. 2021 Apr 8;384(14):1372-1374
pubmed: 33691060
J Immunol. 2007 Apr 1;178(7):4112-9
pubmed: 17371966
J Clin Invest. 2021 May 17;131(10):
pubmed: 33822770
Lancet. 2021 Mar 27;397(10280):1178-1181
pubmed: 33640037
Nat Immunol. 2003 Mar;4(3):225-34
pubmed: 12563257
Nat Immunol. 2007 Jun;8(6):639-46
pubmed: 17486092
Cell Rep Med. 2021 Feb 16;2(2):100204
pubmed: 33521695
Science. 2021 Mar 25;:
pubmed: 33766944
Nat Rev Immunol. 2002 Apr;2(4):251-62
pubmed: 12001996
Sci Transl Med. 2022 Feb 09;14(631):eabi8961
pubmed: 34874183
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Immunity. 2008 May;28(5):710-22
pubmed: 18468462
Cell Rep. 2021 Aug 24;36(8):109570
pubmed: 34390647
N Engl J Med. 2021 Jan 7;384(1):80-82
pubmed: 33270381
J Exp Med. 1997 Nov 3;186(9):1407-18
pubmed: 9348298